We are live on ! Find out more
TCRT icon

Alaunos Therapeutics

140 hedge funds and large institutions have $409M invested in Alaunos Therapeutics in 2019 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 53 increasing their positions, 25 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 10

112% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 25

70% more capital invested

Capital invested by funds: $241M → $409M (+$168M)

13% more funds holding

Funds holding: 124140 (+16)

0.03% more ownership

Funds ownership: 0.26%0.29% (+0.03%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

37% less call options, than puts

Call options by funds: $8.42M | Put options by funds: $13.3M

Holders
140
Holders Change
+16
Holders Change %
+12.9%
% of All Funds
3.04%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
28
Increased
53
Reduced
25
Closed
10
Calls
$8.42M
Puts
$13.3M
Net Calls
-$4.89M
Net Calls Change
-$5.61M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$68.5M +$10.5M +15,297 +24%
Vanguard Group
2
Vanguard Group
Pennsylvania
$65.6M +$5.35M +7,787 +12%
MP
3
MSD Partners
New York
$64M
MVP
4
Miller Value Partners
Florida
$53.9M
State Street
5
State Street
Massachusetts
$32.3M +$618K +899 +2%
DCM
6
Discovery Capital Management
Connecticut
$16M +$4.56M +6,631 +57%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$11.7M +$1.14M +1,656 +14%
Northern Trust
8
Northern Trust
Illinois
$10M +$229K +333 +3%
Morgan Stanley
9
Morgan Stanley
New York
$8.07M +$742K +1,079 +13%
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$6.11M -$752K -1,093 -14%
Charles Schwab
11
Charles Schwab
California
$5.24M +$292K +425 +8%
N
12
Nuveen
North Carolina
$4.05M +$3.19M +4,632 New
Bank of New York Mellon
13
Bank of New York Mellon
New York
$3.77M +$322K +468 +12%
UBS Group
14
UBS Group
Switzerland
$3.23M +$417K +606 +20%
Citigroup
15
Citigroup
New York
$2.63M +$1.55M +2,247 +296%
Invesco
16
Invesco
Georgia
$2.6M +$2.05M +2,976 New
SG Americas Securities
17
SG Americas Securities
New York
$2.21M +$1.59M +2,311 +1,085%
Millennium Management
18
Millennium Management
New York
$2.04M +$1.6M +2,327 New
CB
19
Commerce Bank
Missouri
$1.77M
Group One Trading
20
Group One Trading
Illinois
$1.73M +$526K +765 +63%
D.E. Shaw & Co
21
D.E. Shaw & Co
New York
$1.73M +$1.36M +1,973 New
Barclays
22
Barclays
United Kingdom
$1.67M +$466K +677 +55%
VIA
23
Vident Investment Advisory
Georgia
$1.62M +$1.28M +1,857 New
Swiss National Bank
24
Swiss National Bank
Switzerland
$1.49M +$122K +178 +12%
California State Teachers Retirement System (CalSTRS)
25
California State Teachers Retirement System (CalSTRS)
California
$1.44M +$210K +305 +23%

TCRT Hedge Fund Activity: Q2 2019 in Review

140 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2019, worth a combined $409M — up 70% from $241M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new TCRT positions and 10 closed out — a net gain of 18 holders — while 53 added to existing stakes and 25 trimmed.

The largest buyer was BlackRock, adding an estimated $10.5M. The largest seller was Bank of America, cutting an estimated $1.28M.

  • 140 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2019, up from 124 in Q1 2019.
  • Funds reported $409M of Alaunos Therapeutics stock for Q2 2019, up 70% quarter-over-quarter.
  • 28 funds opened new Alaunos Therapeutics positions in Q2 2019 and 10 closed out, a net change of +18 holders.
  • The largest Alaunos Therapeutics buyer in Q2 2019 was BlackRock, an estimated $10.5M added.
  • The largest Alaunos Therapeutics seller in Q2 2019 was Bank of America, an estimated $1.28M sold.

Based on aggregated 13F filings for Q2 2019.